1101 GMT - AstraZeneca's China troubles seem manageable, Quilter Cheviot healthcare analyst Sheena Berry says in a note. The British pharma company facing potential charges from an import tax allegation against some of its employees in China creates a slight overhang but entails an amount that it can handle, the analyst says. "China has proven to be an overhang on the stock following the fraud investigations of several individuals, and questions remain on exactly what impact this might have on operations in China," she says. Shares are up 5.2% at 117.02 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 06, 2025 06:02 ET (11:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。